皮下注射达雷妥尤单抗治疗复发或难治性多发性骨髓瘤
PAVO(MMY1004)1b期研究评估皮下注射达雷妥尤单抗联合重组人透明质酸酶PH20(DARA-MD)治疗复发或难治性多发性骨髓瘤。1200 mg组(n=8)和1800 mg组(n=45)分别有25.0%和42.2%的患者达到总体缓解,1800 mg剂量达到与16 mg/kg静脉给药相似或更高的血清浓度。皮下给药耐受性良好,1800 mg剂量的药代动力学和缓解与静脉达雷妥尤单抗一致。
要点
- 皮下DARA-MD 1800 mg的药代动力学浓度与16 mg/kg静脉达雷妥尤单抗相似或更高。
- 1200 mg组和1800 mg组总体缓解率分别为25.0%和42.2%。
- 输注相关反应多为1/2级,通常发生在首次输注时。
核心结论
- 皮下注射DARA-MD在复发或难治性多发性骨髓瘤患者中耐受性良好,1800 mg剂量的药代动力学浓度和缓解与静脉达雷妥尤单抗在相似患者人群中一致。
研究设计与样本
- 1b期PAVO(MMY1004)研究,评估皮下注射达雷妥尤单抗联合重组人透明质酸酶PH20(DARA-MD)在复发或难治性多发性骨髓瘤患者中的安全性及药代动力学。
- 患者按已批准的静脉单药给药方案接受皮下达雷妥尤单抗1200 mg(n=8)或1800 mg(n=45)。
- 主要终点为安全性和药代动力学变量。
主要发现
- DARA-MD 1200 mg组最常见的治疗中出现的不良事件为血小板减少症、上呼吸道感染、失眠和食欲下降(各37.5%)。
- DARA-MD 1800 mg组最常见的治疗中出现的不良事件为贫血(33.3%)、上呼吸道感染、发热和腹泻(各26.7%)。
- 1200 mg剂量组1例患者(12.5%)和1800 mg剂量组11例患者(24.4%)发生输注相关反应,一般为1/2级,通常发生在首次输注时。
- 1800 mg剂量达到与16 mg/kg静脉剂量相似或更高的血清浓度。
- 1200 mg和1800 mg DARA-MD的总体缓解率分别为25.0%和42.2%。
关键数值与推荐
- 1200 mg组总体缓解率为25.0%,1800 mg组为42.2%。
- 1200 mg组输注相关反应发生率为12.5%(1/8),1800 mg组为24.4%(11/45)。
临床怎么用
- 皮下注射DARA-MD 1800 mg在复发或难治性多发性骨髓瘤中展现出与静脉达雷妥尤单抗一致的药代动力学浓度和缓解。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM). Currently, daratumumab is administered IV. The phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination with the recombinant human hyaluronidase PH20 enzyme (rHuPH20) in patients with relapsed or refractory MM. Part 1 of the study, reported here, evaluated a mix-and-deliver (MD) formulation of daratumumab and rHuPH20 (DARA-MD) administered by subcutaneous infusion. Patients received subcutaneous daratumumab according to the approved IV monotherapy dosing schedule at 1200 mg (n = 8) or 1800 mg (n = 45). Primary end points were safety and pharmacokinetic (PK) variables. The most common treatment-emergent adverse events with DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreased appetite (37.5% each). Anemia (33.3%), upper respiratory tract infection, pyrexia, and diarrhea (26.7% each) were the most common treatment-emergent adverse events with DARA-MD 1800 mg. One patient in the 1200-mg dose group (12.5%) and 11 patients in the 1800-mg dose group (24.4%) experienced infusion-related reactions, which were generally grade 1/2 and typically occurred at the first infusion. The 1800 mg dose achieved similar or greater serum concentrations compared with the 16 mg/kg IV dose. Overall response rates of 25.0% and 42.2% were achieved with 1200-mg and 1800-mg DARA-MD, respectively. Subcutaneous administration of DARA-MD was well tolerated in patients with relapsed or refractory MM, with the 1800-mg dose exhibiting PK concentrations and responses consistent with IV daratumumab in a similar patient population. This study was registered at www.clinicaltrials.gov as #NCT02519452.
引用
- Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019. PMID: 31270103. doi:10.1182/blood.2019000667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。